FY2026 Earnings Estimate for MDGL Issued By HC Wainwright

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) – Equities researchers at HC Wainwright issued their FY2026 EPS estimates for Madrigal Pharmaceuticals in a research note issued to investors on Wednesday, November 4th. HC Wainwright analyst A. Ghosh expects that the biopharmaceutical company will earn ($2.37) per share for the year. HC Wainwright has a “Strong-Buy” rating on the stock. The consensus estimate for Madrigal Pharmaceuticals’ current full-year earnings is ($6.88) per share. HC Wainwright also issued estimates for Madrigal Pharmaceuticals’ Q4 2026 earnings at $0.95 EPS, FY2027 earnings at $8.29 EPS, FY2028 earnings at $29.07 EPS, FY2029 earnings at $43.84 EPS and FY2030 earnings at $71.25 EPS.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $1.83 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.09) by $2.92. The business had revenue of $431.27 million during the quarter, compared to analyst estimates of $404.17 million. Madrigal Pharmaceuticals had a negative return on equity of 27.08% and a negative net margin of 10.89%. During the same quarter last year, the business posted ($5.08) EPS.

Several other research firms have also commented on MDGL. Truist Financial reaffirmed a “buy” rating and set a $743.00 target price (up from $709.00) on shares of Madrigal Pharmaceuticals in a report on Wednesday. Wolfe Research raised Madrigal Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $605.00 price target for the company in a report on Tuesday, August 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a research report on Thursday, October 15th. Citigroup upped their price objective on Madrigal Pharmaceuticals from $725.00 to $760.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Canaccord Genuity Group raised their price objective on shares of Madrigal Pharmaceuticals from $612.00 to $633.00 and gave the stock a “buy” rating in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $706.87.

Madrigal Pharmaceuticals Trading Down 0.1%

Shares of MDGL stock opened at $400.10 on Friday. The business has a 50-day simple moving average of $489.63 and a 200-day simple moving average of $497.94. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.05 and a quick ratio of 2.94. Madrigal Pharmaceuticals has a 52-week low of $353.54 and a 52-week high of $615.00.

Hedge Funds Weigh In On Madrigal Pharmaceuticals

Several institutional investors have recently modified their holdings of the business. Concurrent Investment Advisors LLC raised its position in Madrigal Pharmaceuticals by 2.0% in the 2nd quarter. Concurrent Investment Advisors LLC now owns 1,034 shares of the biopharmaceutical company’s stock valued at $555,000 after purchasing an additional 20 shares in the last quarter. Fifth Third Bancorp boosted its stake in shares of Madrigal Pharmaceuticals by 3.5% in the 3rd quarter. Fifth Third Bancorp now owns 838 shares of the biopharmaceutical company’s stock valued at $422,000 after buying an additional 28 shares during the period. Commonwealth Equity Services LLC grew its position in shares of Madrigal Pharmaceuticals by 2.7% during the third quarter. Commonwealth Equity Services LLC now owns 1,664 shares of the biopharmaceutical company’s stock worth $839,000 after buying an additional 43 shares in the last quarter. ProShare Advisors LLC grew its position in shares of Madrigal Pharmaceuticals by 5.5% during the third quarter. ProShare Advisors LLC now owns 838 shares of the biopharmaceutical company’s stock worth $422,000 after buying an additional 44 shares in the last quarter. Finally, GAMMA Investing LLC grew its position in shares of Madrigal Pharmaceuticals by 35.4% during the second quarter. GAMMA Investing LLC now owns 172 shares of the biopharmaceutical company’s stock worth $92,000 after buying an additional 45 shares in the last quarter. Institutional investors and hedge funds own 98.50% of the company’s stock.

Insiders Place Their Bets

In other Madrigal Pharmaceuticals news, General Counsel Shannon Kelley sold 664 shares of Madrigal Pharmaceuticals stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $514.97, for a total transaction of $341,940.08. Following the transaction, the general counsel directly owned 11,474 shares of the company’s stock, valued at $5,908,765.78. The trade was a 5.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO William Sibold sold 6,362 shares of the firm’s stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $535.59, for a total value of $3,407,423.58. Following the sale, the chief executive officer directly owned 202,967 shares of the company’s stock, valued at approximately $108,707,095.53. This trade represents a 3.04% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 12,247 shares of company stock worth $6,581,182 in the last three months. 17.60% of the stock is currently owned by corporate insiders.

More Madrigal Pharmaceuticals News

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Rezdiffra real-world data showed improvements in liver stiffness and cardiometabolic health markers. Madrigal presented results from multiple studies at the AASLD meeting, offering further evidence supporting the drug’s use in MASH. Recent coverage also cited Rezdiffra sales of about $1.1 billion. Madrigal real-world data announcement
• Positive Sentiment: Strong results and optimistic forecasts support the growth outlook. Madrigal reported quarterly EPS of $1.83, versus analysts’ expected loss of $1.09, and revenue of $431.27 million, ahead of estimates. HC Wainwright reiterated a Strong-Buy rating and forecast EPS growth from a 2026 loss to $8.29 in 2027 and $71.25 in 2030. Canaccord also raised its price target to $633 and maintained a Buy rating. Coverage of Madrigal’s post-earnings move Canaccord analyst coverage
• Negative Sentiment: Several law firms announced investigations into possible securities-law violations. The notices could add uncertainty and weigh on sentiment, but they are announcements of investigations and do not establish that Madrigal or its executives violated the law. Kaplan Fox investigation notice

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for nonalcoholic steatohepatitis, now known as metabolic dysfunction-associated steatohepatitis (MASH), and other chronic liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.

Madrigal’s lead product is Rezdiffra (resmetirom), an orally administered thyroid hormone receptor beta agonist designed to target key drivers of liver disease, including hepatic fat accumulation and fibrosis.